Host: The Japanese Society of Toxicology
Veklury® (remdesivir, GS-5734TM), the first FDA-approved antiviral for the treatment of COVID-19, is a single diastereomer monophosphoramidate prodrug of an adenosine analogue. It is intracellularly metabolized into the active triphosphate form, which in turn acts as a potent and selective inhibitor of multiple viral RNA polymerases. Remdesivir has broad-spectrum activity against members of the coronavirus family such as SARS-CoV-2, SARS-CoV, and MERS-CoV, as well as filoviruses and paramyxoviruses. The nonclinical safety and efficacy profile of remdesivir will be presented, including results of in vivo efficacy studies, off-target profiling, and repeat dose toxicology studies.
